IBCL-482: Fixed-Duration Subcutaneous Mosunetuzumab (Mosun SC) Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome (CRS), and Non-Inferior Exposure Compared With Intravenous Administration in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Primary Analysis of a Pivotal Phase 2 Study
医学
麻醉
内科学
心脏病学
作者
Nancy L. Bartlett,Laurie H. Sehn,Sarit Assouline,Pratyush Giri,John Kuruvilla,Stephen J. Schuster,Sung Soo Yoon,Keith Fay,Georg Heß,Martin Dreyling,Norma C. Gutiérrez,Eva Cybulski,Antonia Kwan,Elicia Penuel,Samuel Tracy,Denison Kuruvilla,Joseph Chen,Volker Wiebking,Michael C. Wei,Lihua E. Budde